Nintedanib 150 MG [Ofev]

DRUG4 trials

Sponsors

Holdsworth House Medical Practice, Assistance Publique - Hôpitaux de Paris, Sixth Affiliated Hospital, Sun Yat-sen University, PureTech

Conditions

AsbestosisDrug InteractionsPneumoconiosis CoalSARS-Cov-2 Induced Pulmonary FibrosisSilicosisUterine Adhesions

Phase 1

Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib

CompletedNCT06717100

PureTechDrug Interactions

Start: 2024-12-17End: 2025-03-17Updated: 2026-08-13

Phase 2

The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial

Holdsworth House Medical PracticeAsbestosis, Pneumoconiosis Coal, Silicosis

Start: 2020-10-09End: 2025-02-28Target: 100Updated: 2021-02-10

Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions

Sixth Affiliated Hospital, Sun Yat-sen UniversityUterine Adhesions

Start: 2023-12-01End: 2024-12-30Target: 90Updated: 2022-12-02

Phase 3

Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis

RecruitingNCT04541680

Assistance Publique - Hôpitaux de ParisSARS-Cov-2 Induced Pulmonary Fibrosis

Start: 2020-10-29End: 2024-07-31Target: 250Updated: 2024-05-16

Related Papers

Nintedanib for the Treatment of SARS-CoV-2 Induced Pulmonary Fibrosis: A Randomized Clinical Trial (Nintecor)

American Journal of Respiratory and Critical Care Medicine2025-05-011 citations